Replies to post #13398 on Momenta Pharmaceuticals, Inc. (MNTA)

[tony111]

Current stock price suggests market expects that they will sell glatopa in September and MYL will get its drug approved. But I see 2 potential upsides : one they win the patent case with a timely decision and MYL on their CC states that they need to rework the ANDA. Worse case scenario is launching in September with 2 generics still a big pie to share.